Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476835 | 0.78 | ALDH1A1 (0.52) | RAB9ANPC1KMT2AMEN1KDM4E | |
| SCHEMBL5441336 | 0.74 | NPC1 (0.55) | RAB9ANPC1APPACHEBCHE | |
| SCHEMBL3113919 | 0.70 | PDE5A (0.54) | APPACHEBCHEKMT2AMEN1 | |
| SCHEMBL5344442 | 0.69 | STAT1 (0.57) | RAB9ANPC1APPKMT2AMEN1 | |
| SCHEMBL29808634 | 0.68 | SMN1; SMN2 (0.48) | KMT2AMEN1KDM4EALDH1A1MAPT | |
| SCHEMBL22946708 | 0.68 | SMN1; SMN2 (0.48) | KMT2AMEN1KDM4EALDH1A1MAPT | |
| SCHEMBL21542043 | 0.66 | ACHE (0.67) | APPACHEBCHEGAATNF | |
| SCHEMBL30093057 | 0.66 | ACHE (0.67) | APPACHEBCHEGAATNF | |
| SCHEMBL5128296 | 0.66 | NPC1 (0.53) | RAB9ANPC1APPACHEBCHE | |
| SCHEMBL6742014 | 0.65 | TSHR (0.48) | APPACHEBCHEKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099941-A1 | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099941-A1 | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP10, CASP3, CASP4 | RAB9A 1912/4885NPC1 2719/4885APP 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.